Primary extranodal diffuse large B-cell lymphoma in the rituximab era: a single center, retrospective analysis

Reference

• Dawson IM, Cornes JS, Morson BC. Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis. Br J Surg. 1961 Jul;49:80–89.
   PubMed Web of Science ®Google Scholar
• Economopoulos T, Asprou N, Stathakis N, et al. Primary extranodal non-Hodgkin's lymphoma in adults: clinicopathological and survival characteristics. Leuk Lymphoma. 1996 Mar;21(1-2):131–136.
   PubMed Web of Science ®Google Scholar
• d'Amore F, Christensen BE, Brincker H, et al. Clinicopathological features and prognostic factors in extranodal non-Hodgkin lymphomas. Danish LYFO Study Group. Eur J Cancer. 1991;27(10):1201–1208.
   PubMed Web of Science ®Google Scholar
• AlShemmari SH, Ameen RM, Sajnani KP. Extranodal lymphoma: a comparative study. Hematology. 2008 Jun;13(3):163–169.
   PubMed Web of Science ®Google Scholar
• Zucca E, Roggero E, Bertoni F, et al. Primary extranodal non-Hodgkin's lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol. 1997 Aug;8(8):727–737.
   PubMed Web of Science ®Google Scholar
• Zucca E, Roggero E, Bertoni F, et al. Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites. Ann Oncol. 1999 Sep;10(9):1023–1033.
   PubMed Web of Science ®Google Scholar
• Krol AD, le Cessie S, Snijder S, et al. Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. Ann Oncol. 2003 Jan;14(1):131–139.
   PubMed Web of Science ®Google Scholar
• Candelaria M, Oñate-Ocaña LF, Corona-Herrera J, et al. CLINICAL CHARACTERISTICS OF PRIMARY EXTRANODAL VERSUS NODAL DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE COHORT STUDY IN A CANCER CENTER. Rev Invest Clin. 2019;71(5):349–358.
   PubMedGoogle Scholar
• Yun J, Kim SJ, Won JH, et al. Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report. Leuk Res. 2010 Sep;34(9):1175–1179.
   PubMed Web of Science ®Google Scholar
• Yun J, Kim SJ, Kim JA, et al. Clinical features and treatment outcomes of non-Hodgkin's lymphomas involving rare extranodal sites: a single-center experience. Acta Haematol. 2010;123(1):48–54.
   PubMed Web of Science ®Google Scholar
• Reddy S, Pellettiere E, Saxena V, et al. Extranodal non-Hodgkin's lymphoma. Cancer. 1980 Nov 1;46(9):1925–1931.
   PubMed Web of Science ®Google Scholar
• Shi Y, Han Y, Yang J, et al. Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China. Chin J Cancer Res. 2019 Feb;31(1):152–161.
   PubMed Web of Science ®Google Scholar
• Shen H, Wei Z, Zhou D, et al. Primary extra-nodal diffuse large B-cell lymphoma: A prognostic analysis of 141 patients. Oncol Lett. 2018 Aug;16(2):1602–1614.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jan 24;346(4):235–242.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005 Jun 20;23(18):4117–4126.
   PubMed Web of Science ®Google Scholar
• Polyatskin IL, Artemyeva AS, Krivolapov YA. [Revised WHO classification of tumors of hematopoietic and lymphoid tissues, 2017 (4th edition):lymphoid tumors]. Arkh Patol. 2019;81(3):59–65.
   PubMedGoogle Scholar
• Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971 Nov;31(11):1860–1861.
   PubMed Web of Science ®Google Scholar
• Shipp MA. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993 Sep 30;329(14):987–994.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003 Jan 15;21(2):266–272.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Sep 20;32(27):3059–3068.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002 Apr 15;99(8):2685–2693.
   PubMed Web of Science ®Google Scholar
• Wang W, Zhang Y, Zhang L, et al. Intravenous methotrexate at a dose of 1 g/m(2) incorporated into RCHOP prevented CNS relapse in high-risk DLBCL patients: A prospective, historic controlled study. Am J Hematol. 2020 Apr;95(4):E80–e83.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang X, Zou D, et al. Lenalidomide and Rituximab Regimen Combined With Intravitreal Methotrexate Followed by Lenalidomide Maintenance for Primary Vitreoretinal Lymphoma: A Prospective Phase II Study. Front Oncol. 2021;11:701507.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007 Feb 10;25(5):579–586.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Winer ES, Olszewski AJ. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database. Am J Hematol. 2014 Mar;89(3):310–314.
   PubMed Web of Science ®Google Scholar
• Lal A, Bhurgri Y, Vaziri I, et al. Extranodal non-Hodgkin's lymphomas–a retrospective review of clinico-pathologic features and outcomes in comparison with nodal non-Hodgkin's lymphomas. Asian Pac J Cancer Prev. 2008 Jul-Sep;9(3):453–458.
   PubMedGoogle Scholar
• Huang J, Jiang W, Xu R, et al. Primary gastric non-Hodgkin's lymphoma in Chinese patients: clinical characteristics and prognostic factors. BMC Cancer. 2010 Jul 6;10:358.
   PubMed Web of Science ®Google Scholar
• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997 Jun 1;89(11):3909–3918.
   PubMed Web of Science ®Google Scholar
• Møller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation–a population-based study of 1575 cases. Br J Haematol. 2004 Jan;124(2):151–159.
   PubMed Web of Science ®Google Scholar
• Lewin KJ, Ranchod M, Dorfman RF. Lymphomas of the gastrointestinal tract: a study of 117 cases presenting with gastrointestinal disease. Cancer. 1978 Aug;42(2):693–707.
   PubMed Web of Science ®Google Scholar
• Lu CS, Chen JH, Huang TC, et al. Diffuse large B-cell lymphoma: sites of extranodal involvement are a stronger prognostic indicator than number of extranodal sites in the rituximab era. Leuk Lymphoma. 2015 Jul;56(7):2047–2055.
   PubMed Web of Science ®Google Scholar
• Ouyang T, Wang L, Zhang N, et al. Clinical Characteristics, Surgical Outcomes, and Prognostic Factors of Intracranial Primary Central Nervous System Lymphoma. World Neurosurg. 2020 Jul;139:e508–e516.
   PubMed Web of Science ®Google Scholar
• Labak CM, Holdhoff M, Bettegowda C, et al. Surgical Resection for Primary Central Nervous System Lymphoma: A Systematic Review. World Neurosurg. 2019 Jun;126:e1436–e1448.
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer. 2011 Nov 15;117(22):5058–5066.
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, et al. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005 Aug 15;11(16):5984–5992.
   PubMed Web of Science ®Google Scholar
• Ghesquieres H, Chevrier M, Laadhari M, et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†. Ann Oncol. 2019 Apr 1;30(4):621–628.
   PubMed Web of Science ®Google Scholar
• Jahnke K, Thiel E, Martus P, et al. Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol. 2006 Nov;80(2):159–165.
   PubMed Web of Science ®Google Scholar
• Grommes C, Tang SS, Wolfe J, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood. 2019 Jan 31;133(5):436–445.
   PubMed Web of Science ®Google Scholar
• Nayak L, Iwamoto FM, LaCasce A, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017 Jun 8;129(23):3071–3073.
   PubMed Web of Science ®Google Scholar
• Wang YG, Zhao LY, Liu CQ, et al. Clinical characteristics and prognostic factors of primary gastric lymphoma: A retrospective study with 165 cases. Medicine (Baltimore). 2016 Aug;95(31):e4250.
   PubMed Web of Science ®Google Scholar
• Lightner AL, Shannon E, Gibbons MM, et al. Primary Gastrointestinal Non-Hodgkin's Lymphoma of the Small and Large Intestines: a Systematic Review. J Gastrointest Surg. 2016 Apr;20(4):827–839.
   PubMed Web of Science ®Google Scholar
• Ge Z, Liu Z, Hu X. Anatomic distribution, clinical features, and survival data of 87 cases primary gastrointestinal lymphoma. World J Surg Oncol. 2016 Mar 18;14:85.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Montalbán C. Primary diffuse large B-cell lymphoma of the stomach. Crit Rev Oncol Hematol. 2007 Jul;63(1):65–71.
   PubMed Web of Science ®Google Scholar
• Mok TS, Steinberg J, Chan AT, et al. Application of the international prognostic index in a study of Chinese patients with non-Hodgkin's lymphoma and a high incidence of primary extranodal lymphoma. Cancer. 1998 Jun 15;82(12):2439–2448.
   PubMed Web of Science ®Google Scholar
• d'Amore F, Brincker H, Grønbaek K, et al. Non-Hodgkin's lymphoma of the gastrointestinal tract: a population-based analysis of incidence, geographic distribution, clinicopathologic presentation features, and prognosis. Danish Lymphoma Study Group. J Clin Oncol. 1994 Aug;12(8):1673–1684.
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Rossi A, Roggero F, et al. Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. International Extranodal Lymphoma Study Group (IELSG). Ann Oncol. 1999 Dec;10(12):1433–1440.
   PubMed Web of Science ®Google Scholar
• Gao F, Wang ZF, Tian L, et al. A Prognostic Model of Gastrointestinal Diffuse Large B Cell Lymphoma. Med Sci Monit. 2021 Aug 27;27:e929898.
   PubMed Web of Science ®Google Scholar
• Hwang HS, Yoon DH, Suh C, et al. Intestinal diffuse large B-cell lymphoma: an evaluation of different staging systems. J Korean Med Sci. 2014 Jan;29(1):53–60.
   PubMed Web of Science ®Google Scholar
• Hwang HS, Yoon DH, Suh C, et al. A new extranodal scoring system based on the prognostically relevant extranodal sites in diffuse large B-cell lymphoma, not otherwise specified treated with chemoimmunotherapy. Ann Hematol. 2016 Aug;95(8):1249–1258.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Tomita N, Yokoyama M, et al. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era. Cancer. 2012 Sep 1;118(17):4166–4172.
   PubMed Web of Science ®Google Scholar
• Yin X, Xu A, Fan F, et al. Incidence and Mortality Trends and Risk Prediction Nomogram for Extranodal Diffuse Large B-Cell Lymphoma: An Analysis of the Surveillance, Epidemiology, and End Results Database. Front Oncol. 2019;9:1198.
   PubMed Web of Science ®Google Scholar
• Matikas A, Briasoulis A, Tzannou I, et al. Primary bone lymphoma: a retrospective analysis of 22 patients treated in a single tertiary center. Acta Haematol. 2013;130(4):291–296.
   PubMed Web of Science ®Google Scholar
• Huan Y, Qi Y, Zhang W, et al. Primary bone lymphoma of radius and tibia: A case report and review of literature. Medicine (Baltimore). 2017 Apr;96(15):e6603.
   PubMed Web of Science ®Google Scholar
• Derringer GA, Thompson LD, Frommelt RA, et al. Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases. Am J Surg Pathol. 2000 May;24(5):623–639.
   PubMed Web of Science ®Google Scholar
• Vardell Noble V, Ermann DA, Griffin EK, et al. Primary Thyroid Lymphoma: An Analysis of the National Cancer Database. Cureus. 2019 Feb 18;11(2):e4088.
   PubMed Web of Science ®Google Scholar
• Koukourakis G, Kouloulias V. Lymphoma of the testis as primary location: tumour review. Clin Transl Oncol. 2010 May;12(5):321–325.
   PubMed Web of Science ®Google Scholar
• Xu H, Yao F. Primary testicular lymphoma: A SEER analysis of 1,169 cases. Oncol Lett. 2019 Mar;17(3):3113–3124.
   PubMed Web of Science ®Google Scholar
• Vitolo U, Chiappella A, Ferreri AJ, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011 Jul 10;29(20):2766–2772.
   PubMed Web of Science ®Google Scholar
• Kridel R, Dietrich PY. Prevention of CNS relapse in diffuse large B-cell lymphoma. Lancet Oncol. 2011 Dec;12(13):1258–1266.
   PubMed Web of Science ®Google Scholar